Literature DB >> 25900824

Genomic microarray in fetuses with increased nuchal translucency and normal karyotype: a systematic review and meta-analysis.

M Grande1, F A R Jansen2, Y J Blumenfeld3, A Fisher4, A O Odibo5, M C Haak2, A Borrell1.   

Abstract

OBJECTIVE: To estimate the incremental yield of detecting copy number variants (CNVs) by genomic microarray over karyotyping in fetuses with increased nuchal translucency (NT) diagnosed by first-trimester ultrasound.
METHODS: This was a systematic review conducted in accordance with PRISMA criteria. We searched PubMed, Ovid MEDLINE and Web of Science for studies published between January 2009 and January 2015 that described CNVs in fetuses with increased NT, usually defined as ≥  3.5 mm, and normal karyotype. Search terms included: fetal or prenatal, nuchal translucency or cystic hygroma or ultrasound anomaly, array comparative genomic hybridization or copy number variants, with related search terms. Risk differences were pooled to estimate the overall and stratified microarray incremental yield using RevMan. Quality assessment of included studies was performed using the Quality Assessment tool for Diagnostic Accuracy Studies (QUADAS-2) checklist.
RESULTS: Seventeen studies met the inclusion criteria for analysis. Meta-analysis indicated an incremental yield of 5.0% (95% CI, 2.0-8.0%) for the detection of CNVs using microarray when pooling results. Stratified analysis of microarray results demonstrated a 4.0% (95% CI, 2.0-7.0%) incremental yield in cases of isolated NT and 7.0% (95% CI, 2.0-12.0%) when other malformations were present. The most common pathogenic CNVs reported were 22q11.2 deletion, 22q11.2 duplication, 10q26.12q26.3 deletion and 12q21q22 deletion. The pooled prevalence for variants of uncertain significance was 1%.
CONCLUSION: The use of genomic microarray provides a 5.0% incremental yield of detecting CNVs in fetuses with increased NT and normal karyotype.
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  copy number variants; cystic hygroma; genomic microarray; increased nuchal translucency; prenatal diagnosis

Mesh:

Year:  2015        PMID: 25900824     DOI: 10.1002/uog.14880

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  26 in total

1.  Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting.

Authors:  Anne S Bassett; Gregory Costain; Christian R Marshall
Journal:  Prenat Diagn       Date:  2016-11-14       Impact factor: 3.050

2.  Array study in fetuses with nuchal translucency above the 95th percentile: a 4-year observational single-centre study.

Authors:  Edgar Coello-Cahuao; María Ángeles Sánchez-Durán; Inés Calero; María Teresa Higueras; Mayte Avilés García; Carlota Rodó; Nerea Maiz; Alberto Plaja Rustein; Neus Castells-Sarret; Carmen Mediano-Vizuete; Elena Carreras
Journal:  Arch Gynecol Obstet       Date:  2022-04-29       Impact factor: 2.344

3.  Identification of a New Variant of PUF60 Gene: Case Presentation and Literature Review.

Authors:  Daniela Oana Toader; Nicolae Bacalbasa; Radu Ursu; Dragos Cretoiu; Lucian G Pop; Irina Balescu; Florentina Gherghiceanu; Florentina Furtunescu; Daniel Radavoi; Viorica Radoi
Journal:  Cancer Diagn Progn       Date:  2021-07-03

4.  Prenatal Diagnosis Using Chromosomal Microarray Analysis in High-Risk Pregnancies.

Authors:  Ching-Hua Hsiao; Jia-Shing Chen; Yu-Ming Shiao; Yann-Jang Chen; Ching-Hsuan Chen; Woei-Chyn Chu; Yi-Cheng Wu
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

5.  The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening.

Authors:  Victoria K Berger; Mary E Norton; Teresa N Sparks; Monica Flessel; Rebecca J Baer; Robert J Currier
Journal:  Prenat Diagn       Date:  2019-12-02       Impact factor: 3.050

6.  Recurrent increased nuchal translucency: a first trimester presentation of familial 13p satellite deletion.

Authors:  I Uzun; R Has; E Alici; M Ozdemir; C Inan; S Erzincan
Journal:  Balkan J Med Genet       Date:  2016-08-02       Impact factor: 0.519

7.  Clinical experience with single-nucleotide polymorphism-based non-invasive prenatal screening for 22q11.2 deletion syndrome.

Authors:  S J Gross; M Stosic; D M McDonald-McGinn; A S Bassett; A Norvez; R Dhamankar; K Kobara; E Kirkizlar; B Zimmermann; N Wayham; J E Babiarz; A Ryan; K N Jinnett; Z Demko; P Benn
Journal:  Ultrasound Obstet Gynecol       Date:  2016-01-05       Impact factor: 7.299

8.  Clinical utility of array comparative genomic hybridisation in prenatal setting.

Authors:  Luca Lovrecic; Ziga Iztok Remec; Marija Volk; Gorazd Rudolf; Karin Writzl; Borut Peterlin
Journal:  BMC Med Genet       Date:  2016-11-15       Impact factor: 2.103

9.  Population-based impact of noninvasive prenatal screening on screening and diagnostic testing for fetal aneuploidy.

Authors:  Lisa Hui; Briohny Hutchinson; Alice Poulton; Jane Halliday
Journal:  Genet Med       Date:  2017-05-18       Impact factor: 8.822

10.  Enlarged NT (≥3.5 mm) in the first trimester - not all chromosome aberrations can be detected by NIPT.

Authors:  Malgorzata I Srebniak; Merel C de Wit; Karin E M Diderich; Lutgarde C P Govaerts; Marieke Joosten; Maarten F C M Knapen; Marnix J Bos; Gerda A G Looye-Bruinsma; Mieke Koningen; Attie T J I Go; Robert Jan H Galjaard; Diane Van Opstal
Journal:  Mol Cytogenet       Date:  2016-09-07       Impact factor: 2.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.